Spinraza

RSS

nusinersen

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Spinraza. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Spinraza.

For practical information about using Spinraza, patients should read the package leaflet or contact their doctor or pharmacist.

This EPAR was last updated on 02/02/2022

Authorisation details

Product details
Name
Spinraza
Agency product number
EMEA/H/C/004312
Active substance
nusinersen sodium
International non-proprietary name (INN) or common name
nusinersen
Therapeutic area (MeSH)
Muscular Atrophy, Spinal
Anatomical therapeutic chemical (ATC) code
M09
Accelerated assessmentAccelerated assessment

This medicine had an accelerated assessment. This means that it is a medicine of major interest for public health, so its timeframe for review was 150 evaluation days rather than 210. For more information, see Accelerated assessment.

OrphanOrphan

This medicine was designated an orphan medicine. This means that it was developed for use against a rare, life-threatening or chronically debilitating condition or, for economic reasons, it would be unlikely to have been developed without incentives. For more information, see Orphan designation.

Publication details
Marketing-authorisation holder
Biogen Netherlands B.V.
Revision
13
Date of issue of marketing authorisation valid throughout the European Union
30/05/2017
Contact address

Prins Mauritslaan 13
1171 LP Badhoevedorp
The Netherlands

Product information

31/01/2022 Spinraza - EMEA/H/C/004312 - R/0025

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Other nervous system drugs

Therapeutic indication

Spinraza is indicated for the treatment of 5q Spinal Muscular Atrophy.

Assessment history

Related content

How useful was this page?

Add your rating
Average
5 ratings
1 rating
1 rating